Fogacci F, Rizzoli E, Giovannini M, Bove M, D'Addato S, Borghi C, Cicero AFG, Effect of Dietary Supplementation with Eufortyn® Colesterolo Plus on Serum Lipids, Endothelial Reactivity, Indexes of Non-Alcoholic Fatty Liver Disease and Systemic Inflammation in Healthy Subjects with Polygenic Hypercholesterolemia: The ANEMONE Study. Nutrients. 2022 May 18;14(10):209, «NUTRIENTS», 2022, 14, Article number: 2099, pp. 1 - 11 [articolo]Open Access
Bytyçi I, Bajraktari G, Penson PE, Henein MY, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP); Cicero AFG, Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials., «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2022, 88, pp. 1520 - 1528 [articolo]
Cicero AFG, Fogacci F, Zambon A, Toth PP, Borghi C, Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies., «AMERICAN HEART JOURNAL PLUS», 2022, 13, Article number: 100127, pp. 1 - 12 [articolo]Open Access
Palatini, P.; Parati, G.; Virdis, A.; Reboldi, G.; Masi, S.; Mengozzi, A.; Casiglia, E.; Tikhonoff, V.; Cicero, A. F. G.; Ungar, A.; Rivasi, G.; Salvetti, M.; Barbagallo, C. M.; Bombelli, M.; Dell'Oro, R.; Bruno, B.; Lippa, L.; D'Elia, L.; Verdecchia, P.; Angeli, F.; Mallamaci, F.; Cirillo, M.; Rattazzi, M.; Cirillo, P.; Gesualdo, L.; Mazza, A.; Giannattasio, C.; Maloberti, A.; Volpe, M.; Tocci, G.; Georgiopoulos, G.; Iaccarino, G.; Nazzaro, P.; Galletti, F.; Ferri, C.; Desideri, G.; Viazzi, F.; Pontremoli, R.; Muiesan, M. L.; Grassi, G.; Borghi, C., High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid, «EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY», 2022, 29, pp. 1501 - 1509 [articolo]
Cicero, A. F. G.; Fogacci, F.; Di Micoli, A.; Veronesi, M.; Grandi, E.; Borghi, C., Hydroxytyrosol-Rich Olive Extract for Plasma Cholesterol Control, «APPLIED SCIENCES», 2022, 12, Article number: 10086, pp. 1 - 12 [articolo]Open Access
Borghi C, Fogacci F, Agnoletti D, Cicero AFG, Hypertension and Dyslipidemia Combined Therapeutic Approaches, «HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION», 2022, 29, pp. 221 - 230 [articolo]
Borghi C, Fogacci F, Agnoletti D, Cicero AFG., Hypertension and Dyslipidemia Combined Therapeutic Approaches., «HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION», 2022, 29, pp. 221 - 230 [articolo]
Tikhonoff V, Casiglia E, Spinella P, Barbagallo CM, Bombelli M, Cicero AFG, Cirillo M, Cirillo P, Desideri G, D'elia L, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Mallamaci F, Maloberti A, Masi S, Mazza A, Muiesan ML, Nazzaro P, Palatini P, Parati G, Pontremoli R, Quarti-Trevano F, Rattazzi M, Rivasi G, Salvetti M, Tocci G, Ungar A, Verdecchia P, Viazzi F, Virdis A, Volpe M, Grassi G, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA)., Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study, «JOURNAL OF HUMAN HYPERTENSION», 2022, 36, pp. 976 - 982 [articolo]
Cicero A.F.G.; Fogacci F.; Rizzoli E.; Giovannini M.; D'Addato S.; Borghi C.; Grandi E.; Ventura F.; Coppola P.; Ianniello E.; Soldati M.; Piani F.; Iamino I.R.; Palmisano S.; Landolfo M.; Bacchelli S., Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up, «NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES», 2022, 32, pp. 2246 - 2254 [articolo]
Banerjee Y, Pantea Stoian A, Cicero AFG, Fogacci F, Nikolic D, Sachinidis A, Rizvi AA, Janez A, Rizzo M, Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia, «EXPERT OPINION ON DRUG SAFETY», 2022, 21, pp. 9 - 20 [articolo]
Cicero AFG, Fogacci F, Derosa G, D'Angelo A, Ventura F, Rizzoli E, D'Addato S, Borghi C, On Behalf Of The Brisighella Heart Study Group, Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study, «BIOMEDICINES», 2022, 10, Article number: 656, pp. 1 - 11 [articolo]Open Access
Imbalzano E, Orlando L, Sciacqua A, Nato G, Dentali F, Nassisi V, Russo V, Camporese G, Bagnato G, Cicero AFG, Dattilo G, Vatrano M, Versace AG, Squadrito G, Di Micco P, Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 219, pp. 1 - 13 [articolo]Open Access
Fogacci F, Giovannini M, Grandi E, Imbalzano E, Degli Esposti D, Borghi C, Cicero AFG, Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients., «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 4701, pp. 1 - 11 [articolo]Open Access
Fogacci F, Borghi C, Cicero AFG, New evidences on the association between high-density lipoprotein cholesterol and cardiovascular risk: a never ending research story, «EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY», 2022, 29, pp. 842 - 843 [articolo]
Cicero, ARRIGO FRANCESCO GIUSEPPE; Fogacci, F; Di Micoli, A; Veronesi, M; Borghi, C, Noninvasive instrumental evaluation of coenzyme Q10 phytosome on endothelial reactivity in healthy nonsmoking young volunteers: A double-blind, randomized, placebo-controlled crossover clinical trial, «BIOFACTORS», 2022, 48, pp. 1160 - 1165 [articolo]Open Access
